Stay current on the latest news from Wisconsin’s innovation community with these recent headlines:
—TAI Diagnostics, a Wauwatosa-based startup seeking to commercialize a non-invasive test to monitor the health of heart transplant recipients, raised more than $1.7 million from 24 investors, according to an SEC filing that first became public on Thursday. The company’s test measures levels of cell-free DNA, genetic material discharged by the patient’s new heart that enters the bloodstream, to determine whether he or she is in danger of rejecting the organ. TAI Diagnostics has raised more than $10 million in equity and debt financing since launching in 2015, according to regulatory filings.
—RPRD Diagnostics, a Milwaukee-based company developing technology to examine patients’ genetic profiles to predict how they’ll react to particular drugs, announced a partnership with St. Jude Children’s Research Hospital in Memphis, TN. The hospital has a program allowing all pediatric patients who receive care there to receive comprehensive pharmacogenetic testing, which is aimed at evaluating how they’ll metabolize and react physiologically to commonly prescribed medicines. According to a press release, St. Jude will use genotyping tools developed by Thermo Fisher Scientific (NYSE: TMO), which RPRD founder Ulrich Broeckel helped develop, to perform the pharmacogenetic testing. Read the full story here.